BREAST CANCER;
CANCER ADJUVANT THERAPY;
CANCER CHEMOTHERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER PROGNOSIS;
CANCER SURGERY;
CANCER SURVIVAL;
CLINICAL DECISION MAKING;
COST EFFECTIVENESS ANALYSIS;
DISEASE FREE SURVIVAL;
DRUG COST;
DRUG EFFICACY;
EDITORIAL;
HEALTH BEHAVIOR;
HUMAN;
ITALY;
MEDICAL SOCIETY;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RECURRENCE FREE SURVIVAL;
SMALL HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER;
SURVIVAL RATE;
UNITED KINGDOM;
Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: A cohort from an integrated health care delivery system
Fehrenbacher L, Capra AM, Quesenberry CP Jr, et al: Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: A cohort from an integrated health care delivery system. J Clin Oncol 32:2151-2158, 2014
Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: A multi-institutional study
Vaz-Luis I, Otteson RA, Hughes ME, et al: Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: A multi-institutional study. J Clin Oncol 32:2142-2150, 2014
PREDICT Plus: Development and validation of a prognostic model for early breast cancer that includes HER2
Wishart GC, Bajdik CD, Dicks E, et al: PREDICT Plus: Development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer 107:800-807, 2009
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller
Gonzalez-Angulo AM, Litton JK, Broglio KR, et al: High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27:5700-5706, 2009
Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer
Curigliano G, Viale G, Bagnardi V, et al: Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 27:5693-5699, 2009
A phase II study of adjuvant paclitaxel and trastuzumab (APT trial) for node-negative, HER2-positive breast cancer
abstr S1-04
Tolaney SM, Barry WT, Dang CT, et al: A phase II study of adjuvant paclitaxel and trastuzumab (APT trial) for node-negative, HER2-positive breast cancer. Cancer Res 73, 2013 (suppl 24; abstr S1-04)
The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient's experience
Zafar SY, Peppercorn JM, Schrag D, et al: The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 18:381-390, 2013
Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer
abstr 500
Carey LA, Berry DA, Cirrincione C, et al: Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. J Clin Oncol 31:7s, 2013 (suppl; abstr 500)
